In This Article:
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy
Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker
BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Elizabeth Mily as Chief Executive Officer. With more than 30 years of pharma, healthcare investment banking, and strategic leadership experience, Mily will leverage her mission-driven commitment to spearheading the next chapter of the Fund, guiding continued deployment of resources and supporting a comprehensive approach to curing type 1 diabetes. Under her leadership, the T1D Fund expects to build on its current momentum, growing its investment team and expanding strategic partnerships with an eye toward building an ecosystem for delivering new therapies. As the T1D Fund's lead public ambassador, Mily will work to elevate awareness of and investment in leading research, innovation, and the need for cures for type 1 diabetes.
"Elizabeth brings a bold strategic vision to the T1D Fund during an exciting period of our evolution. She is the ideal choice to lead the next chapter as we identify and invest in cutting-edge approaches for treating type 1 diabetes," said Tim Clark, Chair of the Board of Directors at the T1D Fund.
Mily joins the T1D Fund after most recently serving as Executive Vice President, Strategy & Business Development, at Bristol Myers Squibb, where she oversaw the company strategy and approach to sourcing external innovation, including all business development activities, strategic partnerships, alliance management, mergers and acquisitions, and the company's broad equity investing portfolio. Previously, she held senior roles at Barclays, Thermo Fisher Scientific, and Goldman, Sachs & Co., where she led strategy and transactions for the healthcare, life sciences, and biopharma sectors. Mily currently serves on the Board of Solventum Corporation (NYSE: SOLV), where she sits on the Audit and Quality, Science & Technology Committees; she also serves on the Board of Ampersand Biomedicines, a private Flagship Pioneering portfolio company.